Drug
Cirmtuzumab clinical trials
Also written UC-961 and Zilovertamab.
- studies test it
- 7
- open now
- 0
- in phase 3
- 1
- first study started
- 2014
How studies write it
Studies that test it under each name
Name
Development codes
Other names
Studies by the year they started
7 studies that test it; most in 2018 (2)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2016 | 1 |
| 2018 | 2 |
| 2020 | 1 |
| 2022 | 1 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 5
- Phase 2
- 2
- Phase 3
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 2 · Other 5
University of California, San Diego (3) · Oncternal Therapeutics, Inc (2) · Barbara Parker, MD (1) · Thomas Kipps (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses cirmtuzumab is read from its arms, and is right about nine times in ten.
Testing it · 7
- Extension Study of UC-961 (Cirmtuzumab) for Patients With Chronic Lymphocytic Leukemia Treated Previously With UC-961CompletedPhase 1University of California, San DiegoNCT02860676Written as cirmtuzumab
- Cirmtuzumab Consolidation for Treatment of Patients With Detectable CLL on VenetoclaxActive, not recruitingPhase 2University of California, San DiegoNCT04501939Written as Cirmtuzumab
- Study of Cirmtuzumab and Paclitaxel for Metastatic or Locally Advanced, Unresectable Breast CancerCompletedPhase 1Barbara Parker, MDNCT02776917Written as Cirmtuzumab + Paclitaxel
- A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid MalignanciesCompletedPhase 1/2Oncternal Therapeutics, IncNCT03088878Written as Cirmtuzumab (2-16 kg/mg) plus Ibrutinib
- Study of Docetaxel Combined with Cirmtuzumab in Metastatic Castration Resistant Prostate CancerTerminatedPhase 1University of California, San DiegoNCT05156905Written as Cirmtuzumab
- A Study of Zilovertamab and Ibrutinib in Patients With Relapsed or Refractory Mantle Cell LymphomaWithdrawnPhase 3Oncternal Therapeutics, IncNCT05431179Written as Zilovertamab
- UC-961 (Cirmtuzumab) in Relapsed or Refractory Chronic Lymphocytic LeukemiaCompletedPhase 1Thomas KippsNCT02222688Written as cirmtuzumab
Codes
What other systems call cirmtuzumab · ClinicalTrials.gg INT001187
- MeSH (NLM) C000654175cirmtuzumabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) FEH7RQ7B3JZILOVERTAMABConfirmed FDA, NLM
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000654175 | cirmtuzumab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | FEH7RQ7B3J | ZILOVERTAMAB | Confirmed FDA, NLM |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.